Original Article

The Clinical and Pathological Characteristics That Differentiate Cases With “Low Estrogen Receptor Expression” From Triple-Negative Breast Cancer

• Cem Karaali
• Mümin Emiroğlu
• Mustafa Değirmenci
• Murat Keser
• Semra Salimoğlu
• Canan Kelten Talu

The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer

• Zeynep Erdoğan İyigün
• Kezban Nur Pilancı
• Fatmagül Kuşku Çabuk
• Serkan İlgün
• Çetin Ordu
• Tomris Duymaz
• Gül Alço
• Filiz Çelebi
• Dauren Sarsenov
• Filiz İzci
• Alper Öztürk
• Filiz Ağaçayak
• Ülkühan İner Köksal
• Fatma Aktepe
• Yeşim Eralp
• Vahit Özmen

Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients

• Özlem Özdemir
• Baha Zengel
• Demet Kocatepe Çavdar
• Cengiz Yılmaz
• Raika Durusoy

Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR

• Ramesh Omranipour
• Roghiyeh Jalili
• Adel Yazdankhahkenary
• Abdolali Assarian
• Mehrzad Mirzania
• Bita Eslami

Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor–Negative Breast Cancer Chemoprevention

• Fatma Nihan Akkoc Mustafayev
• Diane D. Liu
• Angelica M. Gutierrez
• John E. Lewis
• Nuhad K. Ibrahim
• Vicente Valero
• Daniel J. Booser
• Jennifer K. Litton
• Kimberly Koenig
• Dihua Yu
• Nour Sneige
• Banu K. Arun

Review

AROMATASE INHIBITORS IN BREAST CANCER THERAPY

• Hande Karahan
• Emine Pelin Kelicen